3,399 reports of this reaction
4.4% of all FILGRASTIM reports
#2 most reported adverse reaction
NEUTROPENIA is the #2 most commonly reported adverse reaction for FILGRASTIM, manufactured by Amgen, Inc. There are 3,399 FDA adverse event reports linking FILGRASTIM to NEUTROPENIA. This represents approximately 4.4% of all 76,865 adverse event reports for this drug.
Patients taking FILGRASTIM who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is moderately reported among FILGRASTIM users, representing a notable but not dominant share of adverse events.
In addition to neutropenia, the following adverse reactions have been reported for FILGRASTIM:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 3,399 FDA reports for FILGRASTIM. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 4.4% of all adverse event reports for FILGRASTIM, making it one of the most commonly reported side effect.
If you experience neutropenia while taking FILGRASTIM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.